Investment Review №349. High Hopes

Bassett Furniture Industries (BSET) is a U.S. home-furnishings manufacturer and retailer that combines in-house production with a network of company-owned stores and an e-commerce platform. The investment case is anchored by a solid balance sheet and a broad operational optimization program that has improved manufacturing efficiency, reduced costs, and restored profitability. The company has a net cash position, zero debt, and ample liquidity, supporting continued investment in retail and online expansion as well as steady dividend payments. That said, further earnings improvement largely depends on a recovery in the U.S. housing market, as furniture demand is closely tied to real estate transaction volumes and consumer spending. Despite gradual profitability improvement, the business remains low-margin, leaving earnings sensitive to changes in sales volumes. Key risks include persistently elevated mortgage rates, weak furniture demand, and higher production costs driven by tariffs and inflation.

Our 12-month price target is $22 per share. 

 

Holley (HLLY) is a U.S.-based manufacturer of performance automotive components and accessories, with a portfolio of 65+ specialty brands serving sports-car and modified-vehicle enthusiasts. The thesis is underpinned by Holley’s strong position in the fragmented automotive aftermarket and continued execution on its efficiency program. Management continues to reduce low-margin products, optimize inventory, and cut costs, supporting solid profitability despite volatile demand. Incremental upside could come from a recovery in distributor orders, rising FCF, and gradual deleveraging, which should lift earnings and help narrow the valuation discount. Holley is also strengthening its brands through industry events and direct engagement with the auto-enthusiast community. Principal risks include weaker consumer spending on durables, execution risk around the transformation program, elevated leverage, and the industry’s gradual shift to electric vehicles.

Our 12-month price target is $3.80 per share.

 

Niagen Bioscience (NAGE) is a biotechnology company focused on developing and commercializing products that support cellular health and healthy longevity based on its proprietary nicotinamide-riboside molecule. The investment case is underpinned by rising global interest in extending healthspan, the proliferation of weight-management products, and growing demand for solutions that support metabolism and cellular energy. Key growth drivers include rapid expansion of the ingredients business — most notably the Niagen Plus line of injectable products — and the launch of a telemedicine platform that broadens access to at-home treatment. The company’s extensive patent portfolio protects its core technologies and provides optionality to expand into pharmaceutical and clinical business lines. Niagen is already profitable, generating consistent FCF with room to scale further. Principal risks include potential tightening of dietary-supplement regulation, price competition from lower-cost alternatives, and uncertainty related to legal proceedings in the industry.

Our 12-month price target is $9 per share. 

 

PBF Energy (PBF) is one of the largest independent U.S. refiners, owning six modern refineries with combined capacity of about 1.0 mmbpd. The investment thesis centers on its robust heavy-crude processing capabilities, which support higher margins versus peers, and a strengthening West Coast footprint, where recent refinery closures have tightened fuel supply and supported favorable pricing. The company is improving its balance sheet through post-refinancing deleveraging and plans to resume share buybacks once leverage targets are met. Completion of a major refinery modernization should also support more stable results by FY2027. Key risks include refining-margin compression, sensitivity to geopolitics and crude prices, and potential delays in executing the modernization program.

Our 12-month price target is $42 per share.